Compare HDB & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HDB | GILD |
|---|---|---|
| Founded | 1994 | 1987 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.7B | 154.7B |
| IPO Year | N/A | 1992 |
| Metric | HDB | GILD |
|---|---|---|
| Price | $33.12 | $121.61 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $128.62 |
| AVG Volume (30 Days) | 4.9M | ★ 6.4M |
| Earning Date | 01-18-2026 | 02-10-2026 |
| Dividend Yield | 1.16% | ★ 2.60% |
| EPS Growth | N/A | ★ 6514.05 |
| EPS | 0.53 | ★ 6.42 |
| Revenue | ★ $30,210,861,338.00 | $29,087,000,000.00 |
| Revenue This Year | N/A | $3.63 |
| Revenue Next Year | $9.77 | $3.10 |
| P/E Ratio | $19.35 | ★ $18.96 |
| Revenue Growth | N/A | ★ 2.79 |
| 52 Week Low | $28.89 | $89.02 |
| 52 Week High | $39.81 | $128.70 |
| Indicator | HDB | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 30.57 | 48.53 |
| Support Level | $36.02 | $119.33 |
| Resistance Level | $33.59 | $124.48 |
| Average True Range (ATR) | 0.57 | 2.81 |
| MACD | -0.26 | -0.13 |
| Stochastic Oscillator | 6.90 | 46.58 |
HDFC Bank Ltd is an Indian bank. It operates in the following segments: Treasury, Retail banking, Wholesale banking, and Other banking business. The maximum revenue for the company is generated from its Retail banking segment, which serves retail customers through its branch network and other channels. This segment raises customer deposits and provides loans and other services to customers using different product groups. Its other operations include providing wholesale banking services to corporates, government entities, and other enterprises, generating income from its treasury operations, and performing para-banking activities such as offering credit cards, debit cards, etc. Geographically, the company generates a majority of its revenue from its operations in India.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).